← Leaderboards
Prosper N Boyaka
Ohio State University
$11,131,512
Attributed
$15,784,503
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,784,503 · 6
By mechanism
R01$14,696,502 · 5
P01$1,088,001 · 1
Top collaborators
- Amal O Amer5 shared
- Purnima Dubey5 shared
- Xiaoming He5 shared
- Xi Jiang5 shared
- Jianrong Li5 shared
- Stephanie M M Seveau5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Stacy M Harnish$2,336,092
- Mark P. Foster$5,512,468
- Morton H Friedman$6,226,897
- Zucai Suo$5,008,278
- Ouliana Ziouzenkova Ziouzenkova$418,900
Others in their field
Top investigators on “Pathogen”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$343,790,695
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
- Jeffrey P Krischer · University Of South Florida$130,496,919
- Mark S Klempner · Tufts Medical Center$128,021,180
- Timothy Stedman · American Type Culture Collection$122,230,581
- Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai$99,962,183
Research focus
PathogenAntigensAntigen-Presenting CellsImmune ResponseResponseImmunityVaccinesPathway InteractionsImmuneEpithelial CellsDendritic CellsSignal TransductionEventImmunoglobulin ABindingMucosal ImmunityMucous MembraneSiteAntibodiesPlayCellsInfectionAdjuvantIn Vivo
Grant awards (33)
Host Responses to the Pore-Forming Toxin Listeriolysin O$636,587
R01 · FY2025 · AI
Role of CASP-11 in SARS-CoV-2-induced lung pathologies and long-term immune protection$429,216
P01 · FY2025 · AI · contact PI
Role of CASP-11 in SARS-CoV-2-induced lung pathologies and long-term immune protection$658,785
P01 · FY2024 · AI · contact PI
Host Responses to the Pore-Forming Toxin Listeriolysin O$644,081
R01 · FY2024 · AI
Targeting myeloid cells for regulation of alum-based immunity$616,005
R01 · FY2024 · AI · contact PI
Host Responses to the Pore-Forming Toxin Listeriolysin O$644,081
R01 · FY2023 · AI
Targeting myeloid cells for regulation of alum-based immunity$593,805
R01 · FY2023 · AI · contact PI
Host Responses to the Pore-Forming Toxin Listeriolysin O$671,723
R01 · FY2022 · AI
Targeting myeloid cells for regulation of alum-based immunity$623,624
R01 · FY2022 · AI · contact PI
Targeting myeloid cells for regulation of alum-based immunity$641,926
R01 · FY2021 · AI · contact PI
Host Responses to the Pore-Forming Toxin Listeriolysin O$594,733
R01 · FY2021 · AI
Targeting myeloid cells for regulation of alum-based immunity$658,306
R01 · FY2020 · AI · contact PI
A novel lactic acid bacteria-based norovirus vaccine$592,019
R01 · FY2020 · AI
A novel lactic acid bacteria-based norovirus vaccine$597,289
R01 · FY2019 · AI
Regulation of mucosal IgA and allergic inflammation by intestinal epithelial cells$346,104
R01 · FY2019 · DK · contact PI
A novel lactic acid bacteria-based norovirus vaccine$597,772
R01 · FY2018 · AI
Regulation of mucosal IgA and allergic inflammation by intestinal epithelial cells$346,121
R01 · FY2018 · DK · contact PI
A novel lactic acid bacteria-based norovirus vaccine$607,519
R01 · FY2017 · AI
Regulation of mucosal IgA and allergic inflammation by intestinal epithelial cells$346,135
R01 · FY2017 · DK · contact PI
A novel lactic acid bacteria-based norovirus vaccine$618,184
R01 · FY2016 · AI
Regulation of mucosal IgA and allergic inflammation by intestinal epithelial cells$344,802
R01 · FY2016 · DK · contact PI
Regulation of mucosal IgA and allergic inflammation by intestinal epithelial cells$358,315
R01 · FY2015 · DK · contact PI
Alternative approaches for NALT-based immunity to respiratory pathogens$345,486
R01 · FY2013 · AI · contact PI
Alternative approaches for NALT-based immunity to respiratory pathogens$367,538
R01 · FY2012 · AI · contact PI
Alternative approaches for NALT-based immunity to respiratory pathogens$367,538
R01 · FY2011 · AI · contact PI
Alternative approaches for NALT-based immunity to respiratory pathogens$371,250
R01 · FY2010 · AI · contact PI
Alternative approaches for NALT-based immunity to respiratory pathogens$375,000
R01 · FY2009 · AI · contact PI
MOLECULAR ADJUVANTS FOR NALT-BASED IMMUNITY TO ANTHRAX$341,488
R01 · FY2007 · AI · contact PI
MOLECULAR ADJUVANTS FOR NALT-BASED IMMUNITY TO ANTHRAX$285,682
R01 · FY2006 · AI · contact PI
MOLECULAR ADJUVANTS FOR NALT-BASED IMMUNITY TO ANTHRAX$75,889
R01 · FY2006 · AI · contact PI
MOLECULAR ADJUVANTS FOR NALT-BASED IMMUNITY TO ANTHRAX$362,500
R01 · FY2005 · AI
MOLECULAR ADJUVANTS FOR NALT-BASED IMMUNITY TO ANTHRAX$362,500
R01 · FY2004 · AI
MOLECULAR ADJUVANTS FOR NALT-BASED IMMUNITY TO ANTHRAX$362,500
R01 · FY2003 · AI